Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus PROMETH PLAIN.
CLARITIN REDITABS vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
10 mg orally once daily.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine
Antihistamine